Professor of Physical Medicine & Rehabilitation National Institute of Traumatology and Orthopaedic Rehabilitation, Sherebangla Nagar, Dhaka, Bangladesh Dhaka, Bangladesh
Research Objectives: To investigate the association between SARS-CoV-2 disease and Musculoskeletal Health Complaints (MHC). The specific aims of the study were (1) to compare the 1-month prevalence of MHC among post-acute COVID-19 patients and participants who never tested positive for COVID-19 matched by the former group’s age and gender; (2) to identify the predictors of MHC among all participants, and (3) define the factors independently associated with MHC in post-acute COVID-19 patients.
Design: Case-control study.
Setting: The study was conducted in the general community of Dhaka, Bangladesh.
Participants: The post-acute COVID-19 patients and the people who never tested positive for COVID-19 in the community of the city of Dhaka.
Interventions: The face-to-face interview was taken using a paper-based semi-structured questionnaire, from February 24 to April 7, 2022.
Main Outcome Measures: MHC was measured using the musculoskeletal subscale of subjective health complaints produced by Eriksen et al. Descriptive analysis was conducted to compute MHC prevalence and compare them across groups. Multiple logistic analyses were employed to identify MHC predictors for the participants.
Results: The prevalence of MHC was 38.7%. Adjusted analysis suggested that the SARS-CoV-2 infection was independently associated with MHC (AOR = 3.248,95% CI = 2.307-4.571). Furthermore, unemployment (AOR = 4.156, 95% CI = 1.308-13.208), moderate illness (AOR = 2.947,95% CI = 1.216-7.144), treatment in hospitals’ general word (AOR = 4.388,95% CI = 1.878-10.254) and health complaints after COVID-19 (AOR = 4.796,95% CI = 2.196-10.472) were found to be the predictors of MHC among post-acute COVID-19 patients.
Conclusions: Our study found a robust association between SARS-CoV-2 infection and MHC and recommends that healthcare authorities be prepared to deal with the high burden of MHC among post-acute COVID-19 patients.
Author(s) Disclosures: We have nothing to disclose.
.jpg)
